Premium
Should methyldibromo glutaronitrile continue to be used in the European baseline Series? A REIDAC national cross‐sectional study
Author(s) -
MercaderGarcía Pedro,
PastorNieto María Antonia,
GonzalezPerez Ricardo,
CordobaGuijarro Susana,
GimenezArnau Ana María,
RuizGonzalez Inmaculada,
MoraFernández Verónica,
Miquel Javier,
SilvestreSalvador Juan Francisco,
OrtizFrutos Francisco Javier,
SanzSanchez Tatiana,
RodriguezSerna Mercedes,
PerezFeal Patricia,
SánchezPérez Javier,
HerasMendaza Felipe,
SerraBaldrich Ester,
ZaragozaNinet Violeta,
HervellaGarces Marcos,
GaticaOrtega María Elena,
GarcíaDoval Ignacio,
Descalzo Miguel Ángel,
Borrego Leopoldo
Publication year - 2021
Publication title -
contact dermatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.524
H-Index - 96
eISSN - 1600-0536
pISSN - 0105-1873
DOI - 10.1111/cod.13837
Subject(s) - medicine , patch test , allergy , contact allergy , cross sectional study , epidemiology , allergen , clinical significance , allergic contact dermatitis , patch testing , dermatology , sensitization , cosmetics , contact dermatitis , pediatrics , immunology , pathology
Background Methyldibromo glutaronitrile (MDBGN) was one of the most frequent and relevant allergens found in patch testing at the beginning of this century. In 2008, this preservative was banned from cosmetics in Europe and ever since the prevalence of contact allergy to MDBGN has progressively decreased. Despite that gradual decline, MDBGN is still patch‐tested in most baseline series. This study assessed the frequency of MDBGN sensitization, epidemiological characteristics of allergic patients, and the relevance of positive patch tests in a nationwide Spanish registry (REIDAC). Patients and methods We evaluated consecutively patch‐tested patients in all participating centres. Using these data, we calculated the proportion of patients with positive patch tests to MDBGN from June 2018 to June 2020 and evaluated the relevance of the positive patch tests. Results One hundred and fourteen out of 5072 (2.24 %) tested patients were sensitized to MDBGN. Clinical current relevance was confirmed in only one case. Conclusion Although the frequency of contact allergy to MDBGN remains high, no clinical significance was found in most of these patients (5072 tests needed to obtain one relevant positive result). The clinical usefulness of this allergen seems weak and its continued inclusion in the European baseline series is questionable.